1 Departments of Endocrinology and Metabolism, Clinical Laboratories, and Neonatology, Children's Hospital National Medical Center 111 Michigan Ave, NW Washington, DC; Department of Child Health and Development George Washington University School of Medicine and Health Sciences Washington, DC
2 Department of Pediatrics, University of Colorado School of Medicine, Denver
Propylene glycol (1,2-propanediol) is used in many drug preparations. Although propylene glycol is regarded as having low toxicity in adults, in humans and animals there have been reports of CNS, renal, hematologic, and cardiac toxicity.1-5 The absorption of propylene glycol through large burn wounds has recently been documented as a cause of serum hyperosmolality.6,7
Investigation of the cause of unexplained hyperosmolality in a premature infant led to the finding that several infants in our nursery were hyperosmolar due to administration of propylene glycol in a multivitamin preparation used in parenteral nutrition. This finding raises concern about the relatively large dose of propylene glycol that may be received by very small infants, especially those receiving multiple medications.
This article has been cited by other articles:
![]() |
J. L. Nelsen, C. E. Haas, B. Habtemariam, D. C. Kaufman, A. Partridge, S. Welle, and A. Forrest A Prospective Evaluation of Propylene Glycol Clearance and Accumulation During Continuous-Infusion Lorazepam in Critically Ill Patients J Intensive Care Med, May 1, 2008; 23(3): 184 - 194. [Abstract] [PDF] |
||||
![]() |
B. S. Stonestreet, G. B. Sadowska, J. Leeman, R. C. Hanumara, K. H. Petersson, and C. S. Patlak Effects of acute hyperosmolality on blood-brain barrier function in ovine fetuses and lambs Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2006; 291(4): R1031 - R1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Giacoia, D. L. Birenbaum, H. C. Sachs, and D. R. Mattison The newborn drug development initiative. Pediatrics, March 1, 2006; 117(3 Pt 2): S1 - S8. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Christensen, R. A. Helms, and R. W. Chesney Is Pediatric Labeling Really Necessary? Pediatrics, September 1, 1999; 104(3): 593 - 597. [Full Text] |
||||
![]() |
M. Alloju, M. N. Ehrinpreis, N. J. Rulewski, K. A. Kudsk, B. J. Holcombe, E. Bernstein, J. Temeck, and S. Sobel Shortage of Intravenous Multivitamin Solution in the United States N. Engl. J. Med., July 3, 1997; 337(1): 54 - 55. [Full Text] |
||||
![]() |
Committee on Drugs "Inactive" Ingredients in Pharmaceutical Products: Update (Subject Review) Pediatrics, February 1, 1997; 99(2): 268 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Maytal, G. P. Novak, and K. C. King Lorazepam in the Treatment of Refractory Neonatal Seizures J Child Neurol, October 1, 1991; 6(4): 319 - 323. [Abstract] [PDF] |
||||
![]() |
G. P. Giacoia Intravenous Drug Administration to Low Birthweight Infants Clinical Pediatrics, January 1, 1987; 26(1): 25 - 29. [PDF] |
||||